Role of nintedanib in the treatment of progressive pulmonary fibrosis (PPF) in daily clinical practice.

被引：0
|
作者：
Andres Franch, Fatima [1 ]
Alvarez Martinez, Ignacio Salvador [2 ]
Andujar Llamazares, Mario [3 ]
Segura Ayala, Daniel [3 ]
Meneses Petersen, Elsie Daviana [1 ]
Cabanes Lopez, Luis [1 ]
Novella Sanchez, Laura [1 ]
Ferrando Gabarda, Jose Ramon [1 ]
Meseguer Sisternes, Maria [1 ]
Lluch Tortajada, Inmaculada [1 ]
Naval Sendra, Elsa [1 ]
机构：
[1] Hosp Univ La Ribera, Resp Med Unit, Alzira, Valencia, Spain
[2] Hosp Univ La Ribera, Internal Med Unit, Alzira, Valencia, Spain
[3] Hosp Gen Univ Castellon, Resp Med Unit, Castellon de La Plana, Spain
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA407
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis
    Cottin, Vincent
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (07) : 857 - 865
  • [32] Nintedanib Treatment for Elderly Patients with Idiopathic Pulmonary Fibrosis
    Ochi, Y.
    Kato, M.
    Sasaki, S.
    Nakamura, T.
    Yamada, T.
    Ihara, H.
    Takahashi, F.
    Takahashi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [33] Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
    Wollin, Lutz
    Wex, Eva
    Pautsch, Alexander
    Schnapp, Gisela
    Hostettler, Katrin E.
    Stowasser, Susanne
    Kolb, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (05) : 1434 - 1445
  • [34] Cost-effectiveness of earlier diagnosis of interstitial lung diseases (ILDs) and treatment of its progressive form, progressive pulmonary fibrosis (PPF)
    Walters, Seth
    Soulard, Stephane
    Ye, Weicheng
    Elsen, Aldo
    Kongnakorn, Thitima
    Raj, Sayooj
    Pimple, Pratik
    Dorey, Julie
    Ferreira, Pedro
    Froidure, Antoine
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [35] Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis
    Cameli, Paolo
    Guerrieri, Marco
    Tommaso, Pianigiani
    Sirna, Piersalvatore
    Bergantini, Laura
    D'Alessandro, Miriana
    Elena, Bargagli
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [36] The cost-effectiveness of counselling and consenting patients to start nintedanib for progressive pulmonary fibrosis (PPF) in a group setting: early experiences from a UK tertiary centre
    Zakis, Katie
    Morris, Helen
    Swale, Jenna
    Barker, Annie
    Waye, Rebecca
    Newman, Kate
    Garfoot, Theresa
    Montgomery, Holly
    Rivera-Ortega, Pilar
    Johnston, Janet
    Hayton, Conal
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [37] Nebulised pirfenidone in non-idiopathic pulmonary fibrosis (IPF) progressive pulmonary fibrosis (PPF): first look at FVC data
    West, Alex
    Lawrence, Alexandra
    Bao, Hao
    Nair, Deepthi
    Thompson, Courtney
    Woodhead, Felix
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [38] Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
    Kolb, Martin
    Flaherty, Kevin R.
    Silva, Rafael S.
    Prasse, Antje
    Vancheri, Carlo
    Mueller, Heiko
    Sroka-Saidi, Kamila
    Wells, Athol U.
    INBUILD Trial Investigators
    ADVANCES IN THERAPY, 2023, 40 (12) : 5536 - 5546
  • [39] Treatment of high risk hypertensive patients in daily clinical practice.: The TARVEST study
    Barrios, V
    de la Figuera, M
    Gabrie, R
    Hernández, R
    Calderón, A
    Ruilope, LM
    Redón, J
    JOURNAL OF HYPERTENSION, 2005, 23 : S83 - S83
  • [40] Treatment of pulmonary tuberculosis in private practice.
    Sweet, WS
    BRITISH MEDICAL JOURNAL, 1920, 1920 : 552 - 552
12345